1,048 results match your criteria: "Beijing Tuberculosis and Thoracic Tumor Research Institute[Affiliation]"
Aging Dis
August 2025
Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
China's aging population faces a growing burden of chronic respiratory diseases, straining the public health system. Despite the Healthy China 2030 plan's emphasis on prevention and early detection, systemic barriers, such as low public awareness, urban-rural disparities, fragmented screening models, and uneven specialist distribution, hinder effective pulmonary care for older adults. To address these challenges, a shift toward community-based strategies, including mobile low-dose CT (LDCT) screening units, is proposed.
View Article and Find Full Text PDFEMBO Mol Med
September 2025
Department of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, 300060, Tianjin, China.
Resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) remains a critical clinical challenge in EGFR mutant lung adenocarcinoma (LUAD). Therefore, it is urgent to explore personalized treatment strategies based on distinct resistance mechanisms to reverse EGFR-TKI resistance. Herein, we found that HER2 S310F mutation contributes to third-generation EGFR-TKI resistance, driven by the accumulation of neurotransmitter 5-hydroxytryptamine (5-HT).
View Article and Find Full Text PDFBMC Infect Dis
September 2025
Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
Background: Rifampicin-resistant tuberculosis (RR-TB) remains a significant global public health concern. The elderly population is not only at high risk and among the primary victims of RR-TB but also plays a crucial role in the transmission chain of RR-TB. Their biological particularities, treatment complexities, and social vulnerabilities collectively present substantial challenges to global tuberculosis control.
View Article and Find Full Text PDFACS Appl Bio Mater
August 2025
Translational MedicineCentre, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
Microneedle (MN) technology is rapidly gaining popularity as a skin treatment option, particularly in the field of antiaging. Driven by an aging population and the increasing desire for aesthetic enhancement, the pursuit of effective solutions for skin aging has become a major focus in medical aesthetics, emphasizing the need for innovative treatments. MN technology offers a compelling alternative for creating microchannels in the skin and stimulating natural healing and regeneration processes.
View Article and Find Full Text PDFCell Oncol (Dordr)
August 2025
Department of Minimally Invasive Surgery, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Background: Neoadjuvant targeted therapy has emerged as a promising strategy for resectable non-small cell lung cancer (NSCLC). The analysis of the immune status of tumor microenvironment (TME) after targeted therapies is crucial for understanding the impact of targeted therapy on the TME and providing a basis for synergistic therapeutic approaches.
Methods: Forty-two patients with resectable lung adenocarcinoma (LUAD) were enrolled in this study, and multiplex immunofluorescence technology was used to explore the immune status of the TME after neoadjuvant targeted therapies.
Microbiol Spectr
August 2025
Department of Bacteriology and Immunology, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China.
Unlabelled: Drug resistance in (Mtb), especially isoniazid (INH) resistance, challenges tuberculosis control. This study evaluated droplet digital PCR (ddPCR) against the traditional MeltPro TB assay. A total of 77 INH-resistant samples from Beijing Chest Hospital, China, underwent ddPCR, drug susceptibility testing, and Sanger sequencing.
View Article and Find Full Text PDFJ Nanobiotechnology
August 2025
Translational Medicine Center, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, 101149, China.
Despite the major breakthroughs in immunotherapy, a substantial number of cancer patients continue to confront problems such as low response rates, which restrict the overall effectiveness of existing treatments. There is an urgent necessity to combine advanced biomedical advancements with conventional therapies to improve treatment results. The activation of the cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING) pathway has become a viable technique to elicit innate immune responses against tumors, attracting significant interest as a novel target in cancer therapy.
View Article and Find Full Text PDFJ Transl Med
August 2025
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Background: Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) are effective first-line treatments for advanced non-small-cell lung cancer (NSCLC) patients with EGFR mutations. However, some patients do not respond well, and some experience rapid progression despite initial benefit. This study aims to develop multimodal models integrating pre-treatment histopathological images and clinical variables to predict EGFR-TKIs therapy response and progression-free survival (PFS) in stage IV NSCLC patients.
View Article and Find Full Text PDFJ Inflamm Res
August 2025
Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, People's Republic of China.
Background: Accurate diagnosis of active tuberculosis (TB) remains challenging when facing with no clinical symptom and negative pathogen tests. Metabolic reprogramming is the main characteristic of () infection and has the potential to be used as a diagnostic biomarker for active TB.
Methods: Datasets including healthy donors (HCs) and active TB patients were obtained from the Gene Expression Omnibus database.
Biomed Environ Sci
July 2025
Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing 100191, China.
Objective: Cigarette smoking exacerbates the progression of pulmonary tuberculosis (TB). The role of tertiary lymphoid structures (TLS) in chronic lung diseases has gained attention; however, it remains unclear whether smoking-exacerbated lung damage in TB is associated with TLS. This study aimed to analyze the characteristics of pulmonary TLS in smokers with TB and to explore the possible role of TLS in smoking-related lung injury in TB.
View Article and Find Full Text PDFDalton Trans
August 2025
Translational Medicine Center, Beijing Chest Hospital, Capital Medical University, Beijing, 101149, China.
The misuse of antibiotics has accelerated the spread of antibiotic resistance (AR), making it a major global health threat. Drug-resistant bacteria, such as (), (), (), and (), continue to cause severe infections worldwide. This underscores the need for alternative antibacterial strategies.
View Article and Find Full Text PDFJ Thorac Dis
July 2025
Department of Medical Imaging, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Background: There is still a lack of studies on the optimal sequence of treatment for microwave ablation (MWA) combined with percutaneous biopsy (PB) in the treatment of highly suspected malignant pulmonary nodules (PNs). This study aimed to investigate the feasibility, safety, and efficacy of computed tomography (CT)-guided simultaneous MWA combined with PB in the treatment of highly suspected malignant PNs and discuss the influence of the sequential order of MWA and PB on the treatment outcome.
Methods: From January 2021 to December 2024, 91 patients with single highly suspected malignant PNs underwent synchronous MWA combined with PB.
Genomics Proteomics Bioinformatics
August 2025
China National Center for Bioinformation, Beijing 100101, China.
Tuberculosis (TB) returned as the leading cause of death from a single infectious agent in 2023. Human-macrophages and their secreted exosomes play important roles in combating invading Mycobacterium tuberculosis (Mtb). However, panoramic analysis of the underlying immune mechanism for infected macrophages, package mechanism and anti-TB effect of Mtb treated exosomes remain understood.
View Article and Find Full Text PDFBiomark Insights
August 2025
Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, China.
Background: Patients with extensive disease (ED)-small cell lung cancer (SCLC) commonly suffer a more inferior prognosis than those with limited disease (LD)-SCLC.
Objectives: This study aims to investigate the heterogeneity and prognostic significance of various aneuploid circulating tumor cells (CTCs) subtypes and CTC-associated white blood cell (CTC-WBC) clusters in patients with LD-and ED-SCLC respectively.
Design: This prospective, non-interventional, single-center study included 48 patients with LD-SCLC and 47 patients with ED-SCLC.
Bioorg Chem
August 2025
Pharmaceutical Research Center, Second Affiliated Hospital of Dalian Medical University, Dalian 116044, People's Republic of China. Electronic address:
Euphorbia fischeriana has been traditionally used in Chinese medicine for tuberculosis (TB) treatment since ancient times. In this study, we first report the identification of an abietane-type diterpenoid, 17-hydroxy-jolkinolide B (HJKB), from E. fischeriana, which exhibits potent antimycobacterial activity against both Mycobacterium tuberculosis H37Ra strain and clinical isolates.
View Article and Find Full Text PDFMicrobiol Spectr
September 2025
Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
complex (MAC) is one of the principal pathogenic strains among nontuberculous . Current antibiotics have poor microbiological responses, and repurposed antibiotics are a way to meet clinical needs. Herein, the anti-MAC activity of carrimycin (CAM), a new macrolide, was evaluated vitro and .
View Article and Find Full Text PDFZhonghua Jie He He Hu Xi Za Zhi
August 2025
Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing 101149, China.
The World Health Organization (WHO) published the "" (hereinafter referred to as the ) on April 15, 2025. This guideline primarily presents updates and recommendations based on high-quality evidence-based medical basis across three key aspects: drug-susceptible tuberculosis (DS-TB), drug-resistant tuberculosis (DR-TB), and treatment and care. This article offers an interpretation of the guideline from the perspectives of its recommendations, evidence-based medical basis, core updated content, and clinical applicability.
View Article and Find Full Text PDFInt J Biol Macromol
September 2025
Beijing Chest Hospital, Capital Medical University, Beijing Key Laboratory for Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China. Electronic address:
Mycobacterium tuberculosis (M.tb) manipulates host ferroptosis, a novel form of programmed cell death, to enhance its pathogenicity. However, the precise molecular mechanisms remain poorly be understood.
View Article and Find Full Text PDFFront Oncol
July 2025
Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
Purpose: Chemoradiotherapy combined with consolidation immunotherapy is the standard of care for unresectable stage III non-small cell lung cancer; however, the optimal number of cycles of consolidation immunotherapy remains unknown. This study aimed to investigate the optimal duration of consolidation immunotherapy after chemoradiotherapy.
Materials And Methods: We conducted a real-world, multicenter, retrospective study of patients with unresectable stage III non-small cell lung cancer who underwent consolidation immunotherapy between February 2018 and December 2022 following chemoradiotherapy.
Microorganisms
June 2025
Beijing Chest Hospital, Capital Medical University & Beijing Tuberculosis and Thoracic Tumor Research Institute, Translational Medicine Center, Beijing 101149, China.
Extracellular vesicles (EVs) can be distributed in various bodily fluids, such as serum and urine, and play an essential role in immune regulation, substance transport, and other aspects. Tuberculosis (TB) is an infectious disease caused by (), which places a tremendous burden on public health prevention and control within society. Researchers are committed to developing various diagnoses and treatment plans to eliminate TB effectively.
View Article and Find Full Text PDFProc Natl Acad Sci U S A
August 2025
Center for Tuberculosis Research, Shanghai Public Health Clinical Center, Key Laboratory of Medical Molecular Virology of the Ministry of Education/National Health Commission/Chinese Academy of Medical Sciences (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Medical College, Fudan Univers
Granulomas play a crucial role in the pathology of tuberculosis, but the immune environment governing their formation remains largely unknown. To explore the dynamic changes in the immune microenvironment during the formation of tuberculous granulomas, we infected adult zebrafish with and then examined uninfected and infected kidneys, as well as large and small granulomas in the kidneys. Using single-cell RNA sequencing technology, we identified two major macrophage subpopulations in the hematopoietic tissue (kidney) of zebrafish under uninfected physiological conditions: monocyte derived and tissue-resident macrophages.
View Article and Find Full Text PDFTher Adv Med Oncol
July 2025
General Department, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, No. 9 Beiguan Street, Tongzhou District, Beijing 101149, China.
Background: Coexistent pulmonary tuberculosis and lung cancer (PTB-LC) is a rare type of disease with frequent under- and/or mis-diagnosis. Establishment of a reliable screening model for PTB-LC holds considerable medical and economic significance.
Objectives: We aimed to develop an efficient and convenient tool to identify high-risk individuals for tuberculosis (TB) infection among LC patients based on commonly available parameters in clinical practice.
J Inflamm Res
July 2025
Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University & Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, People's Republic of China.
Purpose: Inflammatory indexes are emerging as sensible prognostic factors for small cell lung cancer (SCLC). However, the prognostic value of dynamic C-reactive protein-to-lymphocyte ratio (CLR) in SCLC patients treated with chemoimmunotherapy remains unclear.
Patients And Methods: This retrospective study investigated 88 SCLC patients who underwent chemoimmunotherapy between January 1, 2020 and December 12 2022.
Cancer Immunol Immunother
July 2025
Department of Radiation Oncology, Beijing Chest Hospital, Capital Medical University & Beijing Tuberculosis and Thoracic Tumor Research Institute, No.9 Beiguan Street, Tongzhou District, Beijing, 101149, China.
Purpose: The value of adjuvant immunotherapy in patients with resectable stage III non-small cell lung cancer (NSCLC) after neoadjuvant chemoimmunotherapy remains unclear. This study aimed to evaluate the prognostic impact of additional adjuvant immunotherapy in patients with stage III NSCLC.
Methods: Patients with stage III NSCLC who received neoadjuvant chemoimmunotherapy followed by radical surgery, with or without adjuvant immunotherapy, were retrospectively enrolled across two hospitals.
J Clin Tuberc Other Mycobact Dis
August 2025
Translational Medicine Center, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
Background: Tuberculosis (TB) is an infectious disease that poses a global hazard to public health. Clinically, the small number and low concentration of Mycobacterium tuberculosis () in some specimens make TB difficult to detect in the laboratory and affect the sensitivity of diagnosis.
Methods: in clinical sputum specimens was purified and concentrated using the double membrane filtration concentration method (DMFCM), which was compared with existing methods and evaluated for application.